Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matsumoto Kinnosuke, Yamamoto Yuji, Shiroyama Takayuki, Kuge Tomoki, Miyazaki Akito, Komuta Kiyohide, Tamiya Motohiro, Nishino Kazumi, Tsukaguchi Akihiro, Tamiya Akihiro, Mihashi Yasuhiro, Uchida Junji, Mori Masahide, Yamauchi Keijiro, Suzuki Hidekazu, Kinehara Yuhei, Moritomo Koki, Shoshihara Nao, Machiyama Hirotomo, Kanaoka Kensuke, Tobita Satoshi, Ueno Kiyonobu, Niki Toshie, Tetsumoto Satoshi, Nishikawa Yuki, Morimura Osamu, Kato Soichiro, Yoneda Midori, Azuma Koji, Osa Akio, Minami Toshiyuki, Nagatomo Izumi, Takeda Yoshito, Kumanogoh Atsushi
Аннотация
METHODS: This multicenter retrospective cohort study included 1340 patients with advanced or recurrent NSCLC receiving first-line ICI-based therapy at 15 Japanese institutions between 2017 and 2022. Preexisting ILD and high-resolution computed tomography (HRCT) patterns were centrally reviewed. Pneumonitis and overall survival (OS) were analyzed using Fine-Gray and Cox models.
RESULTS: Among 1340 patients, 158 (11.8%) had preexisting ILD. Preexisting ILD was independently associated with higher risks of any-grade pneumonitis (adjusted subdistribution hazard ratio [sHR], 2.64; 95% confidence interval [CI], 1.91-3.65) and grade ≥ 3 pneumonitis (adjusted sHR, 2.18; 95% CI, 1.37-3.47) and with worse OS (adjusted HR, 1.36; 95% CI, 1.12-1.66). Pneumonitis onset was followed by an increased risk of death, particularly for grade ≥ 3 pneumonitis (adjusted HR, 2.25; 95% CI, 1.71-2.96), and its clinical course was poorer in patients with ILD. In patients with ILD, probable usual interstitial pneumonia (UIP)/UIP pattern was associated with higher pneumonitis risk (adjusted sHR, 2.18; 95% CI, 1.27-3.74) and shorter OS (adjusted HR, 2.88; 95% CI, 1.80-4.61).
CONCLUSIONS: Among patients receiving first-line ICI-based therapy, preexisting ILD was associated with a higher risk of pneumonitis and shorter survival. In patients with ILD, probable UIP/UIP pattern may identify a subgroup with particularly poor outcomes. Pretreatment HRCT evaluation may therefore be useful for individualized risk-benefit assessment.